technologies that together achieve significantly greater accuracy compared to current tests. The IDA test results have the potential to achieve a much higher positive predictive value (PPV) for presence of disease and greatly decrease unnecessary interventions caused by false positive results. The actionable results will be delivered in a customized Integrated Patient Report (IPR) that facilitates decision making for both the patient and the physician. The company’s initial products will focus on improving the diagnostic accuracy of major women’s diseases, specifically in gynecologic cancers and non-invasive prenatal diagnosis. Celula has an established infrastructure in both the U.S. and China allowing it to develop new products in a significantly more capital efficient manner as well as expand its commercial opportunities beyond the U.S. The company is headquartered in San Diego, California and has development facilities in Chengdu, China.